SPDR S&P Biotech (XBI) Position Maintained by Raymond James Trust N.A.
Raymond James Trust N.A. held its position in shares of SPDR S&P Biotech (NYSEARCA:XBI) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,500 shares of the exchange traded fund’s stock at the end of the second quarter. Raymond James Trust N.A.’s holdings in SPDR S&P Biotech were worth $502,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also bought and sold shares of the company. Ballentine Partners LLC bought a new stake in SPDR S&P Biotech during the second quarter valued at approximately $121,000. National Planning Corp bought a new stake in SPDR S&P Biotech during the second quarter valued at approximately $211,000. Boston Advisors LLC bought a new stake in SPDR S&P Biotech during the second quarter valued at approximately $213,000. Modera Wealth Management LLC bought a new stake in SPDR S&P Biotech during the second quarter valued at approximately $221,000. Finally, Blair William & Co. IL bought a new stake in SPDR S&P Biotech during the second quarter valued at approximately $227,000.
Shares of SPDR S&P Biotech (XBI) opened at 83.66 on Friday. The firm’s 50-day moving average is $79.46 and its 200 day moving average is $73.99. SPDR S&P Biotech has a 12 month low of $53.15 and a 12 month high of $84.90.
The business also recently declared a quarterly dividend, which will be paid on Monday, September 25th. Investors of record on Monday, September 18th will be given a $0.037 dividend. The ex-dividend date is Friday, September 15th. This represents a $0.15 dividend on an annualized basis and a yield of 0.18%.
ILLEGAL ACTIVITY WARNING: This piece was reported by Daily Political and is owned by of Daily Political. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/09/16/spdr-sp-biotech-xbi-position-maintained-by-raymond-james-trust-n-a.html.
SPDR S&P Biotech Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech (NYSEARCA:XBI).
Receive News & Ratings for SPDR S&P Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech and related companies with MarketBeat.com's FREE daily email newsletter.